These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 9308742

  • 1. Female gender and resistance to activated protein C (FV:Q506) as potential risk factors for thrombosis after elective hip arthroplasty.
    Svensson PJ, Benoni G, Fredin H, Björgell O, Nilsson P, Hedlund U, Nylander G, Bergqvist D, Dahlbäck B.
    Thromb Haemost; 1997 Sep; 78(3):993-6. PubMed ID: 9308742
    [Abstract] [Full Text] [Related]

  • 2. Thrombotic risk factors and oral contraception.
    Bokarewa MI, Falk G, Sten-Linder M, Egberg N, Blombäck M, Bremme K.
    J Lab Clin Med; 1995 Sep; 126(3):294-8. PubMed ID: 7665978
    [Abstract] [Full Text] [Related]

  • 3. Probability of recurrence of thrombosis in patients with and without factor V Leiden.
    Rintelen C, Pabinger I, Knöbl P, Lechner K, Mannhalter C.
    Thromb Haemost; 1996 Feb; 75(2):229-32. PubMed ID: 8815565
    [Abstract] [Full Text] [Related]

  • 4. Activated protein C resistance--a major risk factor for thrombosis.
    Rosén SB, Sturk A.
    Eur J Clin Chem Clin Biochem; 1997 Jul; 35(7):501-16. PubMed ID: 9263726
    [Abstract] [Full Text] [Related]

  • 5. Resistance to activated protein C caused by the R506Q mutation in the gene for factor V is a common risk factor for venous thrombosis.
    Dahlbck B.
    J Intern Med Suppl; 1997 Jul; 740():1-8. PubMed ID: 9350175
    [Abstract] [Full Text] [Related]

  • 6. Resistance to activated protein C caused by the factor VR506Q mutation is a common risk factor for venous thrombosis.
    Dahlbäck B.
    Thromb Haemost; 1997 Jul; 78(1):483-8. PubMed ID: 9198201
    [Abstract] [Full Text] [Related]

  • 7. New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis.
    Dahlbäck B.
    Thromb Haemost; 1995 Jul; 74(1):139-48. PubMed ID: 8578447
    [Abstract] [Full Text] [Related]

  • 8. [Activated protein C resistance and venous thrombophilia: molecular genetic prevalence study in the German population].
    Ehrenforth S, Klinke S, von Depka Prondzinski M, Kreuz W, Ganser A, Scharrer I.
    Dtsch Med Wochenschr; 1999 Jun 25; 124(25-26):783-7. PubMed ID: 10414227
    [Abstract] [Full Text] [Related]

  • 9. Activated protein C resistance and the FV:R506Q mutation in a random population sample--associations with cardiovascular risk factors and coagulation variables.
    Lowe GD, Rumley A, Woodward M, Reid E, Rumley J.
    Thromb Haemost; 1999 Jun 25; 81(6):918-24. PubMed ID: 10404768
    [Abstract] [Full Text] [Related]

  • 10. "Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds.
    Simioni P, Scudeller A, Radossi P, Gavasso S, Girolami B, Tormene D, Girolami A.
    Thromb Haemost; 1996 Mar 25; 75(3):422-6. PubMed ID: 8701401
    [Abstract] [Full Text] [Related]

  • 11. APC-resistance is a risk factor for postoperative thromboembolism in elective replacement of the hip or knee--a prospective study.
    Lindahl TL, Lundahl TH, Nilsson L, Andersson CA.
    Thromb Haemost; 1999 Jan 25; 81(1):18-21. PubMed ID: 10348713
    [Abstract] [Full Text] [Related]

  • 12. Resistance to activated protein C as risk factor for thrombosis: molecular mechanisms, laboratory investigation, and clinical management.
    Dahlbäck B.
    Semin Hematol; 1997 Jul 25; 34(3):217-34. PubMed ID: 9241707
    [Abstract] [Full Text] [Related]

  • 13. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C.
    Zöller B, Svensson PJ, He X, Dahlbäck B.
    J Clin Invest; 1994 Dec 25; 94(6):2521-4. PubMed ID: 7989612
    [Abstract] [Full Text] [Related]

  • 14. Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation.
    Dahlbäck B.
    Semin Thromb Hemost; 1999 Dec 25; 25(3):273-89. PubMed ID: 10443959
    [Abstract] [Full Text] [Related]

  • 15. Factor V Q506 (resistance to activated protein C) and prognosis after acute coronary syndrome.
    Holm J, Hillarp A, Zöller B, Erhardt L, Berntorp E, Dahlbäck B.
    Thromb Haemost; 1999 Jun 25; 81(6):857-60. PubMed ID: 10404756
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls.
    Svensson PJ, Zöller B, Dahlbäck B.
    Thromb Haemost; 1997 Feb 25; 77(2):332-5. PubMed ID: 9157592
    [Abstract] [Full Text] [Related]

  • 17. Deletion polymorphism in the angiotensin-converting enzyme gene as a thrombophilic risk factor after hip arthroplasty.
    Philipp CS, Dilley A, Saidi P, Evatt B, Austin H, Zawadsky J, Harwood D, Ellingsen D, Barnhart E, Phillips DJ, Hooper WC.
    Thromb Haemost; 1998 Dec 25; 80(6):869-73. PubMed ID: 9869151
    [Abstract] [Full Text] [Related]

  • 18. Comparison of functional testing for resistance to activated protein C and molecular biological testing for factor V R506Q in 370 patients.
    Montes MA, Fox EA, Longtine JA, Dorfman DM.
    Arch Pathol Lab Med; 1998 Apr 25; 122(4):325-9. PubMed ID: 9648899
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.